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ABSTRACT 
Increasing evidence suggests that much of the neurotoxicity seen in Alzheimer’s 
disease is due to activation of pro-inflammatory cascades of microglia upon 
binding to Amyloid-β peptide (Aβ). Such cascade also promotes Aβ production 
and reduces Aβ clearance leading to increased Aβ accumulation. As these self-
damaging processes participate in the progression of Alzheimer’s, research has 
been aimed at understanding how such activation occurs. Previous studies have 
shown that different receptors of the innate immune system bind to Aβ and 
activate distinctive signaling cascades in microglia. One way by which microglia 
recognize Aβ is through a heterodimer of three cell-surface receptors, Toll Like 
Receptor 4 (TLR4), Toll Like Receptor 6 (TLR6) and the class B scavenger 
receptor type II. In this study, we tested the hypothesis that TLR6 deficiency is 
associated with reduced Aβ accumulation. For this purpose, we quantified fibrillar 
Aβ deposits (plaques) in the 5xFAD mouse model of Alzheimer’s disease in 
comparison to 5xFAD mice with partial deficiency in TLR6 at the age of 5 
 v 
months.  Our data show that 5xFAD mice heterozygous for TLR6, exhibit a 
statistically significant reduction in the total number of plaques and in the surface 
area covered by such plaques in the cortex.  Additional research is needed to 
confirm these results and provide a mechanistic explanation for these findings. 
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Introduction 
 
Of the vast number of diseases affecting the elderly, none have impacted 
as many as Alzheimer’s disease (AD), which affected nearly 36 million people in 
2010 (Honjo, 2012). Patients suffering from AD, a neurodegenerative disorder, 
exhibit progressively worsening dementia including memory loss, impaired 
judgment, physical orientation and language (Candore, 2007). As modern 
medicine improves, the average life expectancy increases. As this happens, the 
prevalence of AD will also increase. In 2000, the Baltimore Longitudinal Study of 
Aging patients, which includes 1236 volunteers, revealed that 155 individuals had 
some form of dementia, of which 114 was AD (Kawas, 2000). This study also 
showed that incidence rate of AD rose from .08% per year in the 60-65 year old 
age group to approximately 6.5% in the 85+ group (Kawas, 2000). A prospective 
cohort study of 2581 patients (10,591 person-years) demonstrated that incidence 
rates triple between the ages of 75 and 79 as well as between 80 and 84, and 
then increases at a much smaller rate (Kukull, 2002). Additionally, an inverse 
relationship was seen between baseline cognitive level, and total years of 
education, and the risk and age of onset of AD (Kukull, 2002). Current studies 
project that by 2030, 66 million people worldwide will be living with dementia, and 
by 2050, that number will be 115 million (Bettens, 2013). In 2010, the cost of 
dementia treatment was an estimated $604 billion, of which 70% was in North 
America and Western Europe (Alzheimer’s Disease International). Several 
 2 
retrospective studies suggest that anti-inflammatory drugs can reduce the risk of 
getting AD and delayed onset (Tahara, 2006; McGeer, 1990; Breitner, 1994; 
Breitner, 1995; Stewart, 1997; Szekely, 2004). 
Neuropathologically, patients exhibit an accumulation of extracellular β-
Amyloid protein (Aβ) senile plaques, intracellular neurofibrillary tangles 
composed of τ protein, activated immune cells including microglia and 
astrocytes, and neuronal degeneration, primarily in the hippocampus and frontal 
cortex (Wang, 2011). As such, Aβ senile plaques and microglial activation by Aβ 
is a pathological hallmark of AD (Hickman, 2008). Chemical studies of brains of 
patients suffering from AD revealed remarkably low levels of the neurotransmitter 
Acetylcholine (ACh) due to depletion of the enzymes responsible for its formation 
(Davies, 1976). This evidence suggested that the pathological alterations in AD 
occur primarily in the hippocampus and the frontal cortex of the brain, two areas 
that rely heavily on ACh (Selkoe, 2002). In fact, it has been shown that Aβ 
activates the Mitogen-activated protein kinase cascade, a pro-inflammatory 
cellular response, in the hippocampus (Dineley, 2001). Recent evidence also 
demonstrated elevated oxidative stress, a result of increased inflammation, in the 
hippocampus and frontal cortex as compared to other brain areas 
(Venkateshappa, 2012). Of note, research has shown that AD pathologically 
involves neuronal loss as well as synaptic loss (Horn, 1996; Ruppin, 1995). 
Furthermore, the loss of neurons does not fully account for the synaptic failure, 
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suggesting that the loss of synapses in itself plays a major pathological role in 
AD progression (Small, 2001).  
While Aβ-induced activation of microglia causes phagocytic clearing of Aβ, 
it also stimulates the microglia to release the respiratory burst molecules, 
resulting in negative neurotoxicity. One method of microglial activation is through 
the Toll Like Receptor (TLR), an innate immune Pattern Recognition Receptor 
(PRR) protein that recognizes ligands of various pathogens. Studies have shown 
that TLR4, as well as the possibility of TLR2, is involved in the neuroinflammation 
that accompanies AD (Walter, 2007). 
Pathophysiology 
Completely understanding the pathology of AD in humans is difficult, as 
the tissue can only be analyzed upon autopsy. Among the known triggers for AD, 
one is a dysfunctional gene producing Aβ (Wenk, 2003). Although the function of 
Amyloid β Precursor protein, a transmembrane protein expressed in large 
numbers in synapses of neurons in the brain, is unknown, it is suspected to be 
involved in cell-cell communication, cell adhesion, platelet aggregation and a vast 
range of neuronal actions including neuroprotection, memory formation and 
synaptic transmission (So, 2013; Aydin, 2012; Bush, 1990; Soba, 2005).  
During post-translational processing, Amyloid Precursor Protein (APP) can 
be proteolytically cleaved by several proteases in two different pathways. In one 
pathway, APP is cleaved by β-secretase followed by the γ-secretase protein 
complex, forming Aβ, a 40-42 amino acid long peptide (Portelius, 2011). In AD, 
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elevated production of this protein, as well as misfolding of Aβ, eventually forms 
dense, insoluble plaques, with an Aβ core surrounded by neuronal processes, 
including microglia, around neurons. A second driving force for AD involves the 
phosphorylation of a a τ protein complex, which stabilizes microtubules and thus 
cytoskeleton. This hyperphosphorylation results in a formation of τ protein 
tangles. The build-up of Aβ leads to hindered synaptic transmission and, 
eventually, apoptosis of cells through the innate immune system. This immune 
response in turn causes inflammation, which will result in further neuronal death. 
As is seen in Figure 1a, normal ageing involves some amount of elevated τ 
phosphorylation, APP production and inflammatory response as neurons age 
and undergo apoptosis. However, Figure 1b demonstrates that in patients 
suffering from AD, decreased clearance of Aβ results in elevated expression of 
this protein, which, along with chronic inflammation, results in microglia 
activation, further intensifying the neuroinflammation, and defective axonal 
movement, resulting in hindered synaptic transmission. All the while, τ protein is 
continually being hyperphosphorylated further aggravating the axonal transport. 
Eventually, the hyperphosphorylation of τ and the uncontrolled production and 
processing of APP results in intracellular neurofibrillary tangles, composed of 
hyperphosphorylated τ, and extracellular senile plaques composed of Aβ, 
microglia, neurons and cellular debris that cannot be properly removed by the 
impaired microglia. 
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Figure 1: Healthy versus Alzheimer’s Disease Ageing. Pathological 
Ageing involves the same processes seen in healthy patients in an uncontrolled 
manner, which results in the inflammatory response. Aβ accumulation from APP 
processing is one major pathological alteration that results in plaques, and τ 
hyperphosphorylation results in neurofibrillary tangles hindering cellular function. 
Figure taken from Krstic, 2013. 
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AD arises in two forms, familial and sporadic AD (Bettens, 2013). In Early 
Onset Familial AD (EOFAD), genetic mutations in the APP gene can result in 
intensified production of all forms of the protein, or just Aβ42, results in early-
onset of dementia and AD before the age of 65 (So, 2013; Selkoe, 2004). The 
most common variation of these mutations, about 90% of early-onset AD, is a 
missense mutation in the transmembrane protein Presenilin 1 (PS1), and PS2 to 
a lesser extent. PS1 is part of γ-secretase and works with β-secretase to create 
Aβ42 (Braga-Neto, 2013). EOFAD comprises 5% of AD cases in hospitals and 
includes about 230 different mutations in genes coding proteins involved in APP 
synthesis and cleavage (Wu, 2012; Cruts, 2012; Lleó). Interestingly, increasing 
research suggests that although the Amyloid cascade is responsible for EOFAD, 
another mechanism is responsible for sporadic, late-onset AD (LOAD) (Krstic, 
2012; Herrup, 2010). One factor that strongly implicated in the cause of sporadic 
LOAD is the presence of the ε4 allele of Apolipoprotein E (Krstic, 2013; Corder, 
1993). 
Innate Immune System 
The innate immune system is one of two lines of defense in the body, and 
protects the host by differentiating between molecular structures that are, and are 
not, present when healthy. To detect these changes, the innate immune system 
relies on PRRs on various immune cells circulating in the body. One of these 
cells, monocytes, differentiates in different body tissues into specialized cells. In 
the brain and the rest of the central nervous system (CNS), disease or insult will 
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cause monocytes to develop into microglia and act as the main immune defense. 
Because the Blood Brain Barrier (BBB) separates the brain from the rest of the 
body, most infections cannot reach the CNS. As such, immune cells of the CNS 
are much more specialized, and scavenge for plaques and damaged neurons. 
Additionally, microglia must find antigens, engulf them, and use cytokines to act 
as antigen presenting cells (APCs) for T lymphocytes, the cytotoxic part of the 
adaptive immune system, since most antibodies are not small enough to cross 
the BBB. Once a microglia is activated it will begin the respiratory burst, releasing 
the reactive oxidative species (ROS) hydrogen peroxide, superoxide radicals and 
nitrogen monoxide (NO), pro-inflammatory cytokines and lysing enzymes 
(Khanna, 2001). While this burst is often mandatory for damage repair and 
antigen removal, it can paradoxically cause neuronal cytotoxicity and death.  
Alzheimer’s Disease and Immune Response 
In AD, microglia detect and bind to Aβ deposits, phagocytize the protein 
and activate the microglia resulting in a release of respiratory burst molecules 
and lytic enzymes. While some of these pathways are beneficial, the release of 
ROS, NO and lytic enzymes has been linked to the neurotoxic effects of AD. One 
activated molecule, Interleukin-1β (IL-1β), is critical in the inflammatory response 
of microglia to Aβ, and is often seen elevated in brains of containing Aβ (Halle, 
2008; Heneka, 2007). Microglia are found in large numbers in plaques of late AD 
patients and models (Hickman, 2008). Data show that decreased levels of 
microglia in the early stages of AD development leads to elevated Aβ protein 
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levels, increased plaque numbers and early mortality (El Khoury, 2007). This 
data supports the hypothesis that microglia provide a neuroprotective role in AD.  
Interestingly, some data suggest that as mice age, microglia become 
deficient in expression of Aβ receptors and Aβ-degrading enzymes, but maintain 
production of pro-inflammatory cytokines, thus shifting to a pathology-inducing 
state (Hickman, 2008). To detect plaques, microglia express receptors such as 
class A scavenger receptor (SR-A) and class B scavenger receptor type II, or 
cluster of differentiation 36 (CD36), two PRRs that, when bound to an antigen 
such as Aβ, activate different pathways. SR-A stimulates microglial phagocytosis 
of Aβ without inducing microglial activation. In contrast, evidence suggests that 
CD36 is responsible for microglial activation upon Aβ binding, resulting in 
pathogenesis (El Khoury, 2003). Indeed, El Khoury et al. showed that CD36 
deficient microglia exhibit greatly reduced levels of some pro-inflammatory 
cytokines, including Tumor Necrosis Factor α (TNFα) and Interleukin 1β IL-1β (El 
Khoury, 2003).  
CD36 is a PRR that can bind multiple ligands, including from pathogen or 
host. CD36 has been implicated in the Staphylococcus aureus-induced activation 
of TLR2/6 signaling (Stuart, 2005). By studying CD36+/- Drosophila 
melanogaster, Stuart et al. demonstrated that phagocytosis of S. aureus requires 
CD36 to activate the TLR2/6 heterodimer signaling pathway, and that the 
absence of CD36 in S. aureus-positive flies led to extreme bacteremia. Of note, 
recent evidence has shown that CD36 forms another dimer with TLRs 4 and 6 
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(Stewart, 2010). In this study, Stewart et al. studied the role of CD36, TLR4 and 
TLR6 in Aβ-induced microglia activation of Nuclear Factor κ Light Chain 
Enhancer of Activated B Cells (NF-κB), a protein responsible for the production 
of many pro-inflammatory cytokines such as IL-1β (Mori, 1996; Libermann, 
1990).  Stewart et al. discovered that macrophages deficient in CD36, or a CD6-
TLR4/6 dimer failed to activate NF-κB, whereas an increase in CD36 expression 
in cells caused a two-to-three-fold increase of TLR4/6 signaling. Additionally, it 
was seen that concurrent expression of all three components, TLR 4, TLR6 and 
CD36, was required for maximal immune response to Aβ (Stewart, 2010), 
suggesting that a signal complex exists between the three, and it regulates the 
response of the innate immune system to endogenous ligands, whereas the 
CD36-induced activation of TLR2/6 signaling was triggered by exogenous 
bacterial ligands. Therefore, Stewart at el. generated mice deficient in CD36, 
TLR4, TLR6 or TLR2 and observed the inflammatory response to Aβ. As 
hypothesized, mice lacking CD36, TLR4 or TLR6 presented a reduced 
inflammatory response, including reduced release of the respiratory burst, in 
response to Aβ, whereas TLR2+/- mice exhibited an inflammatory response equal 
to wild-type mice, providing further evidence that a CD36-TLR4-TLR6 complex 
mediates the innate immune response to host ligands.  Interestingly, Stewart also 
found hindered levels of IL-1β in TLR4+/-, TLR6+/-, and CD36+/- mice, implicating 
this signaling complex in this cytokine’s activation and release. 
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Toll-Like Receptor 6 
Microglia rely on TLRs, another set of PRRs, to aid in detection of 
pathogen-associated molecular patterns (PAMPs) including bacteria, fungi, 
viruses and even some host molecules (Bell, 2003). After the discovery of the 
first TLR (Nomura, 1994), studies have demonstrated the vital role they play in 
regulation of genes critical for host defense. Currently, there are 10 known 
human TLRs, all containing an extracellular leucine-rich-repeat (LRR) structural 
motif and cytoplasmic receptor, Toll-Interleukin-1 receptor (TIR), responsible for 
signal initiation (Stewart, 2010). Due to their prominent role in innate immunity, it 
is no surprise that high levels of TLRs can be found in organs regularly involved 
in immune response, such as the lung and spleen (Downes, 2010). Recent 
evidence suggests that although the brain is considered immune privileged, 
messenger RNA can be found for TLRs 1-10 in the microglia of mouse models. 
This allows microglia to quickly respond to endogenous and exogenous 
substances (Downes, 2010).  
It has been demonstrated that a TLR6-TLR2 heterodimer binds diacyl 
lipopeptides of mycoplasma, bacteria that lack a cell wall, whereas the 
TLR1/TLR2 heterodimer recognized triacyl lipopeptides, suggesting that TLR6 is 
involved in the distinguishing between the fine subtleties of bacterial lipopeptides  
(Takeda, 2002).  
Once TIR domains initiate a signal, four proteins carry the signal to 
proteins and transcription factors (TF) that activate an inflammatory response. 
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These proteins are Myeloid Differentiation Factor 88 (MyD88), MyD88 Adaptor 
Like Protein (MAL), Toll Receptor Associated Activator of Interferon (TRIF) and 
Toll Receptor Associated Molecule (TRAM) (Beutler, 2004). A fifth domain, sterile 
α- and armadillo-motif-containing protein(SARM), regulates TLR signaling 
(Downes, 2010). MyD88, which is used by all TLRs but TLR3, is composed of 
three subunits. One domain binds to TIR on the TLR, and one, phosphorylates 
Interleukin Receptor-associated Kinase (IRAK) 1 and 4, which will then activate 
downstream proteins, and result in elevated transcription of pro-inflammatory 
genes (Downes, 2010). Due to its vital role, TLR signaling is termed MyD88 
dependent or independent. Figure 2 shows the proteins involved in the 
inflammatory response of each TLR-induced pathway. Upon activation, TLR6 
and TLR4 complex induces MyD88 to phosphorylate downstream proteins, 
causing the activation of NF-κB, eventually resulting in the release of pro-
inflammatory cytokines and the respiratory burst molecules (Stewart, 2010).  
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Figure 2: Signal Cascade of TLR Proteins. Many Toll Like Receptors share 
their signaling cascades and result in pro-inflammation. Seen here, TLR6 shares 
its mechanism with TLR2 and with most of the TLR4 cascade, providing insight 
into how these receptors may interact. Figure taken from Wang, 2011. 
 
 
TLRs may also play a major role in AD pathology. Research has already 
suggested that TLR2 binds to Aβ and activates neuroinflammation, inhibition of 
TLR2 resulted in a lesser inflammatory response and elevated plaque clearance 
by microglia (Liu 2012), and that the expression of some TLRs, specifically TLR2 
and 4, is elevated in blood of AD patients (Zhang, 2012). However, other studies 
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have shown that TLR2 acts as a receptor to clear Aβ plaques, and a deficit of 
TLR2 would lead to elevated Aβ plaque levels and exacerbated memory loss 
(Hanke, 2011; Richard, 2008). Interestingly, studies have shown that a lack of 
TLR4 leads to elevated Aβ plaque levels, suggesting that TLR4 is involved in 
clearance of plaques (Arroyo, 2011; Tahara, 2006). TLR9 is believed to increase 
Aβ clearance, protect against toxicity by plaques, reduce plaque formation, and 
and improve mental ability loss (Drouin-Ouellet, 2010; Iribarren, 2005; Doi, 2009; 
Scholtzova, 2009).  
As can be seen in Figure 3, evidence suggests that TLRs increase 
recognition of Aβ plaques by interacting with other cell surface receptors such as 
CD36, CD47 and SR-A (Arroyo, 2011; Bamberger, 2003; Reed-Geaghan, 2009). 
TLRs can also form heterodimers with themselves, allowing detection of even 
more ligands. In one such heterodimer, TLR2/6, it was seen that TLR6 inhibited a 
Aβ-triggered TLR2-mediated inflammatory response (Liu, 2012). Another dimer is 
CD36, which acts as a TLR4/TLR6 co-receptor. In fact, research has shown that 
the cell surface receptor for Aβ is composed of a collection of different proteins, 
including SR-A, CD36, TLR2, TLR4, TLR6 and TLR9 (Bamberger, 2003; 
Paresce, 1996; Reed-Geaghan, 2009; Stewart, 2010). TLR4+ and TLR6+ 
microglia deficient in CD36 did not activate pro-inflammatory cytokines in 
response to oxidized low-density lipoprotein (LDL), a major TLR ligand (Stewart, 
2010). Furthermore, it has been shown that CD36 is required for Aβ-induced 
microglia activation (El Khoury, 2003). Once one of the TLRs is activated, a cell-
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signaling cascade is activated including phosphorylation of other proteins. This 
cascade ends in elevated levels of pro-inflammatory gene transcription through 
TFs and the respiratory burst of ROS and pro-inflammatory cytokines. In 
agreement with their detrimental role, it has been seen that TLR levels negatively 
correlate with brain function (Zhang, 2012). Due to their important role, some 
have suspected that TLRs may play a genetic role in AD, although results have 
differed. While some studies have showed a TLR4 polymorphism to be 
associated with AD in the Italian population (Minoretti, 2006; Balistreri, 2008), this 
same polymorphism was not seen in the Chinese population (Wang, 2011). 
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Figure 3: Role of Toll Like Receptors in Aβ Plaque Activation of Microglia. 
TLR2 and TLR6 recognize extracellular Aβ plaques, sometimes by forming 
heterodimers with other cell surface proteins, including CD36. Once bound to Aβ, 
TLRs activate downstream effectors and cause transcription of pro-inflammatory 
genes and the release of neurotoxic molecules.  Furthermore, these 
heterodimers allow the TLR complex to bind multiple different ligands. Upon 
binding to a ligand, most TLRs will activate MyD88 which will phosphorylate 
downstream proteins, including IRAK 1 or 4. 
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Toll Like Receptors and Aging 
 Evidence suggests that the functions of the innate immune system, and 
particularly those induced by TLRs, undergo drastic changes in late life 
(Kollmann, 2012; McElhaney, 2009; Panda, 2009; Panda, 2010; Shaw, 2010). 
Whereas TLR2 levels in monocytes and conventional dendritic cells and TLR9 in 
plasmacytoid dendritic cells do not decrease with age, expression of TLR1 and 4 
in monocytes, and TLR1, TLR7 and TLR8 in both dendritic cells is decreased in 
older people (Panda, 2010; van Duin, 2007; Jing, 2009; Shaw, 2010). 
Furthermore, the innate immune system of the elderly is commonly found in a 
state of chronic inflammation, including elevated IL-6 and TNF-α (Kollmann, 
2012; Franceschi, 2007; Panda, 2010; Qian, 2012). This elevation in TLRs as 
well as pro-inflammatory cytokines may provide further reasoning behind the 
worsening of AD pathology with age, and a worsened neurotoxicity resulting from 
these elevations.  
Although little is known about TLR6 apart from its ability to form 
heterodimers with TLRs 2 and 4, it has been shown that activation of this TLR 
will up-regulate pro-inflammatory molecules, including IL-1β, Protein Kinase C 
and Phosphatidylinositide-3-Kinase (PI3K) (Won, 2012). Recent evidence also 
suggests that mRNA of TLRs 2 and 6 is down-regulated in mice with a high fat 
diet, suggesting a role for adipose in immunity regulation (Betanzos-Cabrera, 
2012). Additionally, an assay of 24 single nucleotide polymorphisms (SNP) 
revealed that a SNP in TLR6, SNP rs5743827, was associated with decreased 
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risk of Bronchopulmonary Dysplasia (Winters, 2013), a lung disorder in children 
born prematurely characterized by chronic inflammation in the lungs (Mosca, 
2011). Another TLR6 SNP, SNP in Ser249Pro, was correlated with a decreased 
risk for asthma, as well as a reduced inflammatory response in hypertensive 
women (Tantisira, 2004; Sales, 2010).  In sequencing full exons, Ma et al. 
showed that people with a TLR6-249S SNP had considerably elevated risk of 
tuberculosis (Ma, 2007). 
Hypothesis of Current Study 
 In this study, we aim to prove that TLR6 plays a neurotoxic and plaque-
protecting role in AD. We hypothesize that, when activated by Aβ, TLR6 will 
activate down-stream effectors that result in cytotoxicity of neurons and other 
cells of the CNS. Due to the large assembly of proteins that bind Aβ on the 
surface of microglia, we predict that the absence of TLR6 will result in a reduced 
level of pro-inflammation, allowing other receptors, such as SR-A, to activate Aβ 
clearance, rather than pro-inflammation, leading to reduced plaque count in 
TLR6 deficient mice in comparison with 5XFAD mice. As it has been shown that 
the absence of TLR2 and 4 result in elevated Aβ aggregates, we believe that 
TLR6 works through its CD36 co-receptor to bind Aβ, and, rather than 
phagocytize the plaque, activate the respiratory burst, which will result in 
neurotoxicity and neuronal cell death seen in late-stage AD. 
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Methods 
Mouse 
Protocols for this study were approved by the Massachusetts General 
Hospital Institutional Animal Care and Use Committee and met the guidelines for 
the humane care of animals of the United States National Institutes of Health 
(NIH publication no. 5377-3 1996). For this study, heterozygous TLR6+/- 
Alzheimer’s mice were compared to control heterozygous 5XFAD Alzheimer’s 
mice with normal TLR6 levels. Figure 4 details the breeding strategy used to 
produce the desired mice. Homozygous TLR6 knockout mice on the 5XFAD+/- 
background were bred in house. The 5XFAD mice, considered generation F0, 
were purchased from Taconic Labs. The F0 5XFAD were bred with the TLR6+/- 
mice to generate 5XFAD-TLR6+/- heterozygotes and used as test subjects at the 
age of five months, as it has been demonstrated that 5XFAD mice at this age 
exhibit a large amount of Aβ plaques. Five TLR6+/- were used as the 
experimental group and seven 5XFAD with normal TLR6 levels were used as 
controls. Mice were sacrificed using a Carbon Monoxide gas. Blood was then 
drawn from the heart using the anti-coagulant heparin and centrifuged at 1000g 
for five minutes to separate immune cells from erythrocytes. The supernatant, 
composed of white blood cells, was then drawn and stored at -80°C for further 
analysis. Next, one hemisphere of the brain was extracted and stored in 2% 
paraformaldehyde (PFA) for twenty-four hours and then transferred to sucrose 
until used for analysis. PFA is prepared by diluting 10ml 16% PFA with 70ml 
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PBS. For the sucrose, we dissolved 150g of sucrose in a volume of 500ml H2O. 
This solution is then filtered and aliquotted into 50ml Falcon tubes for storage. 
The second hemisphere was also acquired and flash frozen in dry ice and stored 
in -80°C for further analysis. Lastly, 2 sections of each tail were acquired and 
stored for genetic assessment as needed. 
Figure 4: Breeding Strategy for TLR6+/- mice. To produce the desired 
genotype of TLR6 heterozygotes, TLR6 homozygous knockouts were mated with 
a 5XFAD background and then with the resulting heterozygote TLR6-5XFAD. 
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Sectioning & Staining 
After a period of at least twenty-four hours in sucrose, brains were 
sectioned at 12µm using a cryostat at -25°C. 10 sections were taken from each 
subject and were stored at -80°C for a period of no less than twenty-four hours. 
From the ten sections, three were then stained with Thioflavin-S and held at 4°C. 
This provided us with 15 sections of TLR6+/- mice to compare to 21 sections from 
5XFAD mice, to provide more accurate results. No less than three sections could 
be analyzed per subject as the statistical significance would be too small. For the 
stain, .05% Thioflavin-S solution was prepared by adding .1g Thioflavin-S to 
20mL distilled water and vacuuming out particulates. To prepare the 70% ethanol 
(EtOH), 15mL distilled water and 35mL 100% EtOH were combined. Lastly, 4',6-
diamidino-2-phenylindole (DAPI) was prepared using 2µL DAPI and 10mL 
distilled water.  
For the staining, slides were removed from -80°C and stored in room 
temperature for five minutes. Distilled water was then added to the slide for a 
couple seconds and aspirated. .05% Thioflavin-S was then added to the slide for 
five minutes in the dark. Thioflavin-S was aspirated and 70% EtOH was added 
for another five minutes in the dark. EtOH was aspirated and distilled water was 
added for three thirty-second intervals. After this wash, slides were kept at room 
temperature for five minutes to allow the tissue to dry and adhere to the slide. 
Once dry, DAPI was added for one minute in the dark and aspirated. Slides were 
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washed another three times at thirty-second intervals and dried. Vectashield was 
then added to reduce the possibility of air bubbles and slide covers placed. 
Slides were sealed with quick-dry nail polish, in order to prevent movement of the 
slide cover that could insult the tissue and to prevent particulates from entering, 
and stored at 4°C until use. Sections were scanned for the Thioflavin-S and DAPI 
fluorescent stains using TissueFax by Tissuegnostics and analyzed for plaques 
using the free software ImageJ.  
Statistical Analysis 
Due to its prominent presence in the hippocampus and frontal cortex, Aβ 
plaques these areas alone were considered, and compared in 5XFAD versus 
TLR6+/- mice. Using the 15 experimental sections from the TLR6+/- mice and the 
21 sections from 7 5XFAD mice, the two brain structures were analyzed for the 
absolute number of plaques, the total surface area in micrometers that the 
plaques occupied, and the percent area of the brain this constituted. Statistical 
Analysis was performed using Student’s t-test using Microsoft’s Excel statistical 
software. P < 0.05 was considered significant. 
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Results 
Decreased Aβ levels in TLR6 deficient AD mice 
 The first step in understanding the role of Toll-Like Receptor 6 on 
Alzheimer’s disease is to understand the role it plays in clearing Aβ. To assess 
this involvement, we analyzed the plaque count of five mice positive for AD but 
lacking TLR6 and compared the results to seven mice of the same strain with 
normal TLR6 levels. To most accurately gauge the results, we looked at the 
percent of the brain area inhabited by Aβ plaques in order to prevent influence by 
size of mice or plaques. Table 1 provides the amount of plaques and their area in 
both test subjects. The seven 5XFAD mice presented with an average of 1,197 
plaques per cortex, whereas the five TLR6+/- mice exhibited 584, a 61% decrease 
(Table 2, Figure 6). Furthermore, the area covered with plaques in the 5XFAD 
was 14,486µm2, while plaques occupied only 8,248µm2 in the TLR+/- experimental 
mice, a 43% reduction from the 5XFAD (Table 3, Figure 5). Due to its smaller 
size, absolute variations in the hippocampus were smaller. However, as there is 
already little space to contain plaques, the 1,013µm2 reduction in occupied area 
represents a 31% decrease. Similarly, total plaque count in the 5 TLR6+/- mice 
was an average of 91 plaques less than the average of the 7 5XFAD mice, which 
signifies a 36% reduction in TLR6+/- mice. 
As is seen in Table 4, 5XFAD mice all presented with approximately 15% 
of the frontal cortex covered in Aβ plaques with no outliers, while there was a 
greater variation in the hippocampus, with an average of 21% covered in plaques 
 23 
and a 13% difference between the highest and the lowest plaque counts. In the 
TLR6 deficient mice, however, there was a much greater variation in both the 
hippocampus and the frontal cortex. In the cortex, an average of 12% is seen, 
with one outlier at 20%, 6% more plaque area than the next highest. 
Interestingly, the hippocampus showed a high level of plaque concentration, with 
an average of 22% if the drastic outlier of 2% is disregarded. Figures 5, 6 and 7 
compare the averages of area (Figure 5), plaque count (Figure 6) and percent 
area occupied by plaques (Figure 7) between the 5XFAD and experimental mice. 
These graphs demonstrate the large differences in the number of plaques and 
the surface area they cover between TLR6 deficient and TLR6+. In scanning the 
whole surface of the brain (Figure 8), the difference between the 5XFAD and the 
TLR6+/- mice is quite evident, whereas scans of the hippocampus (Figure 9) 
reveal that a smaller change occurred in this brain structure. 
Using the Student’s t-test, we noticed that the decrease in the total 
number of plaques and the surface area they occupied in the cortex were both of 
significant difference (p=0.006 and 0.02 respectively). However, none of the 
findings in the hippocampus, nor the percentage of area occupied, were of 
significant difference, as p > 0.05 in all cases. 
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Table 1. Aβ Plaque Count and Surface Area. 
  Cortex Hippocampus 
  5XFAD TLR6+/- 5XFAD TLR6+/- 
Plaque Count 1197.52 584.87 252.14 161.21 
Total Plaque Area 
(µm) 14486.73 8247.8 3253.43 2240.33 
Percent Area 15.27% 12.47% 21.11% 20.00% 
 
Table 2. Aβ Plaque Numbers in Hippocampus and Cortex 
  Cortex Hippocampus 
  5XFAD TLR6+/- 5XFAD TLR6+/- 
  1232.67 342 258 202.67 
  1116 914.33 282.33 226.33 
  748.67 378.67 250.33 3.5 
  810 436.33 105.33 187.67 
  1496.67 853 383.33 133.33 
  1506   183.67   
  1472.67   302   
Average 1197.5 584.87 252.14 161.21 
 
Table 3: Total Area in Brain Structures Occupied by Aβ Plaques. 
  Cortex Hippocampus 
  5XFAD TLR6+/- 5XFAD TLR6+/- 
  12068.77 4593.93 2325.13 2511.44 
  11108.39 11482.29 2552.85 2905.02 
  10617.73 6466.55 2556.10 68.05 
  12208.05 5137.42 1689.39 2630.34 
  16507.95 13558.83 5170.81 2362.72 
  20318.94   3621.73   
  18577.28   4857.98   
Average 14486.73 8247.80 3253.43 2240.33 
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Table 4: Fraction of Brain Structures Covered by Aβ Plaques. 
  Cortex Hippocampus 
  5XFAD TLR6+/- 5XFAD TLR6+/- 
  11.78% 7.97% 17.97% 17.77% 
  11.46% 13.58% 16.67% 22.70% 
  13.86% 12.58% 19.46% 2.21% 
  15.82% 7.30% 14.83% 27.46% 
  16.85% 20.91% 27.84% 23.90% 
  19.44%   24.15%   
  17.72%   26.87%   
Average 15.27% 12.47% 21.11% 20.00% 
 
 Figure 5: Average Area Containing Aβ Plaques. In analyzing the plaque 
levels in each brain structure, a much larger area was occupied by Aβ in both the 
cortex (left) and hippocampus (Right) in the 5XFAD mice (dark) than in the 
experimental mice (light). (cortex p=.0227, hippocampus p=.1487). 
 
*** 
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Figure 6: Average Plaque Count in Brain Structures. The brain of 5XFAD 
mice exhibited many more plaques than that of the TLR6+/- mice. (cortex 
p=.0063, hippocampus p=.0792). 
Figure 7: Average Percent Area of AD Brain Covered with Aβ Plaques. Our 
results revealed a larger fraction of the brain covered with Aβ plaques in the 
brains of 5XFAD (white) over TLR6+/- mice (dark). A larger difference was seen in 
the frontal cortex (left) than in the hippocampus (right). (cortex p=.2776, 
hippocampus p=.6081). 
 
 
*** 
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Figure 8: Aβ TLR6 absence and Aβ Accumulation. 5XFAD AD mouse (a) 
exhibits elevated levels of Aβ (green) throughout the brain as compared to 
TLR6+/- mouse (b). 
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Figure 9: Aβ Accumulation in TLR6 Deficient Hippocampus. The 
hippocampus of 5XFAD AD mouse (a) presents with a large amount of Aβ 
(green) in comparison to the hippocampus of a TLR6+/- mouse (b). 
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Discussion 
Alzheimer’s disease is pathological ageing characterized by a markedly 
elevated level of microglia and Amyloid β protein congregates in the brain. Being 
an age-dependent disease, as the mean age of survival of the population rises, 
so too does the incidence of LOAD among the elderly. Symptoms of AD involve 
drastic mental changes, including confusion, memory loss and difficulty with 
higher-level thinking such as solving problems.  
The leading cause of dementia, AD affects many millions of people 
worldwide, especially over the age of 65. Because most research suggests Aβ 
and hyperphosphorylated τ as the causative agents, most biopharmaceutical 
drug development has been geared to treating these to mechanisms, mostly by 
reducing Aβ accumulation (DuBoff, 2012; Palop, 2010; Schenk, 2012; Lee, 2011; 
Mullane, 2013). Unfortunately, over 100 compounds attempting to treat AD failed 
between the years of 1998-2011 (Mullane, 2013; Pharmaceutical Research and 
Manufacturers of America). Therefore, current treatment options aim at pain and 
symptom management, such as Acetylcholinesterase Inhibitors and donepezil, 
and often show little efficacy (Kaduszkiewicz, 2005; Raina, 2008; Mullane, 2013).  
During normal post-translational modifications of the APP protein, an 
excess production of Aβ may occur. Aβ first accumulates in the hippocampus 
and the frontal cortex. As Aβ accumulates, microglia clear the protein through 
phagocytosis by binding Aβ. However, as Aβ becomes pathologically produced, 
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microglia cannot properly clear all the Aβ, and thus get stuck in aggregates of the 
protein. This accumulation of microglia and Aβ results in the pathological Aβ 
plaque, which induces the release of microglial respiratory burst elements, 
including NO and ROS, and pro-inflammatory cytokines. These elements then 
act in a neurotoxic manner and damage neurons and cause cell death. Aided by 
τ hyperphosphorylation, the AD senile plaque begins to hinder proper cellular 
function and synaptic transmission, resulting in some of the symptoms seen in 
AD. 
Due to their large variety of functions, microglia express a wide range of 
receptors. Research has shown that of these, TLRs are some of the most 
important. TLRs can bind both endogenous ligands and exogenous ligands 
including bacterial LPS and viral double stranded RNA. TLRs can recognize a 
large span of molecules by creating homo- and hetero-dimers. Once recognized, 
most TLRs induce a MyD88-dependent signaling cascade that results in 
inflammation through pro-inflammatory cytokines and molecules, such as IL-1β. 
In this experiment, we studied the function of the TLR6 receptor protein in 
the immune system recognition of Aβ and the receptor’s contribution to AD 
pathology. We hypothesized that mice deficient in TLR would exhibit a less 
severe pathology, as shown by reduced number of Aβ plaques. Though not 
conclusive, our data suggest that the absence of TLR6 allowed mice to more 
thoroughly clear Aβ protein in the frontal cortex, as 61% fewer plaques were 
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found in the frontal cortex of the TLR6+/- mice as compared to 5XFAD mice 
suffering from AD, with a statistical significance (p < 0.05). However, the TLR6 
deficiency did not support clearance of Aβ from the hippocampus, as the results 
were not statistically significant (p > 0.05). We also theorized that TLR6 works 
through a complex with the cell surface receptor CD36. As was previously 
shown, CD36 works in conjuncture with TLRs 4 and 6 to aid in the clearing of Aβ 
protein, and that these three proteins, which can form a heterotrimer, regulate the 
activation and release of pro-inflammatory cytokines and molecules of the 
respiratory burst previously shown to have deleterious and pathological effects 
on the host (Stewart, 2010). Of interest, it has been previously demonstrated that 
mice deficient in CD36 demonstrate diminished levels of the pro-inflammatory 
cytokine IL-1β (Janabi, 2000; El Khoury, 2003) and a decreased inflammatory 
response. As TLR6 is an activator for IL-1β expression, this finding further 
suggests a connection in the mechanism of action of TLR6 and CD36. The 
discovery of TLRs, and their critical role in host recognition of antigens, has 
provided vast information on the capabilities of the innate immune system and its 
ability to recognize and eliminate foreign pathogens. Unfortunately, the 
mechanism by which TLRs act is profoundly unknown.  
Although the analysis of our data revealed a decrease in overall Aβ 
accumulation in the brains of mice lacking TLR6, the results are skewed. While 
we witnessed large differences in the number of plaques and the total amount of 
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room they acquired, the percent of area covered in Aβ plaques was very small, 
under a 3% difference in the frontal cortex and 2% in the hippocampus, with no 
statistical significance. However, there was a significant standard deviation. In 
our test subjects, the percent of the hippocampus covered by plaques was at 
20%, but there was a standard deviation of 50%, suggesting the presence of a 
negative outlier, which when removed, resulted in a percent coverage greater 
than of the 5XFAD. Conversely, when the positive outlier was removed from the 
TLR6+/- cortex data, the average percent covered was under 10% almost 6% 
lower than the 5XFAD.  We believe that this was caused by a problem in the 
analysis of total surface area of the brains, as visual comparison reveals that 
these percents do not match the visible change. We are working on discovering 
what this error was in order to correct the calculations. 
Alternatively, there was almost a 50% decrease in the actual number of 
plaques in the cortex of the TLR6 deficient mice as the 5XFAD mice (8,247 
versus 14,486, p < 0.05) and a 33% decrease in the hippocampus, 2,240 in 
TLR6+/- mice compared to 3,253. Similarly, an overall decrease in the area 
containing Aβ plaques was seen. In the cortex, the 5XFAD specimens had an 
average surface area of 1,200µm2 containing plaques whereas the experimental 
mice had only 585µm2, with statistical significance (p < 0.05). In the 
hippocampus, a decrease of approximately 33% was seen again, as 5XFAD 
mice had an average of 252µm2 of brain tissue containing plaques whereas the 
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experimental mice lacking TLR6 had only 161µm2. 
Our results suggest that TLR6 is involved in the response to Aβ 
accumulation, and therefore contributes to AD pathology. Based on work by 
Stewart et al., our findings propose that it is possible that TLR6 works in 
conjuncture with CD36 and TLR4 to activate a pro-inflammatory response that 
somehow hinders the clearance of Aβ protein, resulting in elevated protein 
aggregates, and Aβ plaques. By releasing pro-inflammatory cytokines and 
neurotoxic elements like NO and ROS may cause neuronal apoptosis that then 
release cellular debris. As this debris accumulates, it further aggravates the 
already building Aβ aggregates, resulting in plaques that prevent clearance of 
Aβ. As this occurs, microglia will remain in a constant state of pro-inflammation, 
which will further damage neurons.  
Fallbacks of the Study and Future Research 
As our results complement each other in two of the three analysis scales, 
it is assumed that the percent of the tissue containing Aβ plaques was distorted. 
This could be because the tissue was smaller in the experimental mice. This 
disagreement between the results represents a major problem with this study, 
which is the little amount of information available. Firstly, there is only one time 
point. This instant in time of five months may not provide the full picture, as the 
lack of TLR6 may delay the development of plaques rather than reduce it totally. 
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Furthermore, as few mice were used as test subjects, our results could have 
been very skewed by the outliers we encountered. This could distort the results 
and suggest a link that is not actually present. In order to remedy this, we are 
analyzing data from three and four months of age as well in order to construct a 
progression of the pathology. Additionally, this study may not correctly show the 
full scheme, as only one fluorescent stain was used and it may not react with all 
Aβ. Therefore, we will be analyzing the data with more stains, including mouse 
anti-CD11b antibody, which recognizes CD11b on macrophages, and will 
therefore provide information on the number of microglia activated in both the 
5XFAD and the TLR6+/- mice.  
Although this data suggests a correlation between TLR6 levels and the 
progression of AD pathology, more research is required to verify the theory that 
TLR6 and CD36 work in conjuncture to activate pro-inflammatory cytokines and 
further the neurotoxicity seen in patients suffering from AD. A study of the 
animals’ behavior would be beneficial in seeing if this altered pathology impacts 
the mice and their actions, including survival, mating pattern, feeding pattern and 
social interaction. Although our results are promising, much research will be 
needed to show how TLR6 differs from the other cell surface receptors in its 
mechanism, as a deficiency in the other receptors results in reduced microglial 
phagocytosis, elevated Aβ aggregation, and worsened AD pathology. These 
results may also suggest a novel mechanism of action for TLR6 separate of 
TLR4 cooperation. To test this, a study should be done to see the effect of 
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eliminating various cell surface receptors associated with TLRs, as a similar 
result to ours would give more insight into the TLR6-related plaque protection we 
witnessed. 
Future Implications: From Discovery to Drug 
While our results suggest a novel action cascade for microglia in the 
presence of Aβ, much more research is needed to validate and explain these 
results. After these pre-clinical studies are able to determine the cause of these 
results, it will be possible to develop drugs to solely disable this cascade while 
allowing microglia to continue clearing Aβ. Such a drug would be able to reduce 
the neurotoxic effects seen in AD pathology and prevent worsening of the 
condition.  After finding a molecule that properly disables TLR6-mediated 
inflammation, the safety of such a drug would be assessed, first in animal models 
and then in humans. This would be very important, especially in a drug targeting 
TLR6 itself, because of the vast array of effects the TLR receptors have. As 
such, it is possible that a drug that inhibits TLR6 function in the brain will have a 
similar effect in the rest of the tissue, making the host more susceptible to 
secondary infection or disease. Assuming the drug passes these safety 
measures, large-scale studies would be needed to assess the efficacy of this 
drug. Although much more work is required to possibly bring this drug to market, 
the benefits far exceed the cost, as there is currently no drug that effectively 
prevents the worsening of AD, making this a novel possibility. 
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Conclusion 
Using a small-scale mouse study, we demonstrated with statistical 
significance that the absence of TLR6 supports clearance of Aβ in the frontal 
cortex by 61% (p < 0.05), but not in the hippocampus (p > 0.05). Upon analysis, 
we deduce that Aβ binding to TLR6 activates a previously unknown cascade that 
activates a pro-inflammatory response without supporting microglial clearance of 
Aβ. This discovery provides novel possibilities for drug targeting, and offers a 
new advantage in battling one of the most troublesome disorders to afflict the 
elderly worldwide.  
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